Related Experiment Video

Updated: Jun 21, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Advances in immunotherapies in ovarian cancer

Ruveyda Ayasun1, Dmitriy Zamarin2,3,4

  • 1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

Journal for Immunotherapy of Cancer
|June 19, 2026
PubMed

Insights

Ovarian cancer immunotherapy shows promise but faces challenges. New antigen-directed therapies and combination strategies are being explored to improve patient outcomes and overcome resistance.

Area of Science:

  • Oncology
  • Immunology
  • Gynecologic Oncology

Background:

  • Ovarian cancer (OC) is a leading cause of cancer death among women.
  • Tumor-infiltrating lymphocytes (TILs) are present in OC, but immune checkpoint inhibitors offer limited benefit.
  • This necessitates exploration of novel immunotherapeutic strategies.

Purpose of the Study:

  • To review the current landscape of immunotherapy for ovarian cancer.
  • To examine factors limiting therapeutic efficacy.
  • To discuss emerging strategies and future directions.

Main Methods:

  • Review of current clinical investigations in ovarian cancer immunotherapy.
  • Analysis of biological and clinical factors influencing treatment response.
  • Discussion of emerging combination therapies and biomarker-driven approaches.

Main Results:

  • Several antigen targets (e.g., mesothelin, folate receptor-α) are under investigation.
  • Adoptive cell therapies, bispecific antibodies, vaccines, and ADCs are being explored.
  • Limited clinical benefit from current immune checkpoint inhibitors highlights resistance mechanisms.

Conclusions:

  • Antigen-directed immunotherapies show potential for ovarian cancer treatment.
  • Overcoming resistance requires rational combinations and biomarker-guided strategies.
  • Integrated genomic and immune profiling is crucial for advancing OC immunotherapy.
Keywords:
ImmunotherapyOvarian CancerTumor microenvironment - TME

More Related Videos

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...